Effects of ticagrelor versus clopidogrel in troponin-negative patients with low-risk ACS undergoing ad hoc PCI

Journal of the American College of Cardiology

Volumn 67, Issue 6, 2016, Pages 603-613

  Angiolillo, Dominick J ^a   Franchi, Francesco ^a   Waksman, Ron ^b   Sweeny, Joseph M ^c   Raveendran, Ganesh ^d   Teng, Renli ^e   Zhao, Yonggang ^e   Carlson, Glenn ^e   Khan, Naeem ^e   Mehran, Roxana ^c  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b WASHINGTON HOSPITAL CENTER   (United States)

^c MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^e ASTRAZENECA   (United Kingdom)

Author keywords

cardiovascular diseases; coronary artery disease; platelet aggregation inhibitors; platelet function tests; platelet reactivity

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; TICAGRELOR; ADENOSINE; ANTITHROMBOCYTIC AGENT; PURINERGIC P2Y RECEPTOR ANTAGONIST; TICLOPIDINE; TROPONIN;

ACUTE CORONARY SYNDROME; ADULT; AGED; ARTICLE; BLEEDING; CARDIOVASCULAR RISK; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENCY; DRUG SAFETY; DYSPNEA; FEMALE; HUMAN; LOADING DRUG DOSE; LOW RISK PATIENT; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PERCUTANEOUS CORONARY INTERVENTION; PHARMACODYNAMICS; PHASE 4 CLINICAL TRIAL; PLATELET REACTIVITY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; THORAX PAIN; THROMBOCYTE AGGREGATION INHIBITION; UNSTABLE ANGINA PECTORIS; ANALOGS AND DERIVATIVES; BLOOD; BLOOD CLOTTING PARAMETERS; CLINICAL TRIAL; DOSE RESPONSE; DRUG EFFECTS; FOLLOW UP; MIDDLE AGED; ORAL DRUG ADMINISTRATION; PREOPERATIVE CARE; PROCEDURES; THROMBOCYTE AGGREGATION; TREATMENT OUTCOME;

ACUTE CORONARY SYNDROME; ADENOSINE; ADMINISTRATION, ORAL; AGED; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PERCUTANEOUS CORONARY INTERVENTION; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PLATELET FUNCTION TESTS; PREOPERATIVE CARE; PROSPECTIVE STUDIES; PURINERGIC P2Y RECEPTOR ANTAGONISTS; TICLOPIDINE; TREATMENT OUTCOME; TROPONIN;

EID: 84958818167     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2015.11.044     Document Type: Article

References (33)

1. D. Capodanno, K. Dharmashankar, and D.J. Angiolillo Mechanism of action and clinical development of ticagrelor, a novel platelet ADP P2Y12 receptor antagonist Expert Rev Cardiovasc Ther 8 2010 151 158
2. P.A. Gurbel, K.P. Bliden, K. Butler, and et al. Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study Circulation 120 2009 2577 2585
3. L. Wallentin, R.C. Becker, A. Budaj, and et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes N Engl J Med 361 2009 1045 1057
4. A. Bellemain-Appaix, S.A. O'Connor, J. Silvain, and et al. Association of clopidogrel pretreatment with mortality, cardiovascular events, and major bleeding among patients undergoing percutaneous coronary intervention: a systematic review and meta-analysis JAMA 308 2012 2507 2516
5. A. Bellemain-Appaix, M. Kerneis, S.A. O'Connor, and et al. Reappraisal of thienopyridine pretreatment in patients with non-ST elevation acute coronary syndrome: a systematic review and meta-analysis Br Med J 349 2014 g6269
6. E.A. Amsterdam, N.K. Wenger, R.G. Brindis, and et al. 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines J Am Coll Cardiol 64 2014 e139 e228
7. S. Windecker, P. Kolh, F. Alfonso, and et al. 2014 ESC/EACTS guidelines on myocardial revascularization Eur Heart J 35 2014 2541 2619
8. M. Roffi, C. Patrono, J.P. Collet, and et al. 2015 ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation Eur Heart J 37 2016 267 315
9. D. Capodanno, and D.J. Angiolillo Pretreatment with antiplatelet drugs in invasively managed patients with coronary artery disease in the contemporary era: review of the evidence and practice guidelines Circ Cardiovasc Interv 8 2015 e002301
10. T.M. Bashore, S. Balter, A. Barac, and et al. 2012 American College of Cardiology Foundation/Society for Cardiovascular Angiography and Interventions expert consensus document on cardiac catheterization laboratory standards update: a report of the American College of Cardiology Foundation Task Force on Expert Consensus documents developed in collaboration with the Society of Thoracic Surgeons and Society for Vascular Medicine J Am Coll Cardiol 59 2012 2221 2305
11. D.J. Angiolillo, J.A. Jakubowski, J.L. Ferreiro, and et al. Impaired responsiveness to the platelet P2Y12 receptor antagonist clopidogrel in patients with type 2 diabetes and coronary artery disease J Am Coll Cardiol 64 2014 1005 1014
12. W.S. Nimmo, and L.F. Prescott The influence of posture on paracetamol absorption Br J Clin Pharmacol 5 1978 348 349
13. U.S. Tantry, L. Bonello, D. Aradi, and et al. Consensus and update on the definition of on-treatment platelet reactivity to adenosine diphosphate associated with ischemia and bleeding J Am Coll Cardiol 62 2013 2261 2273
14. H. Jneid, D.L. Bhatt, R. Corti, and et al. Aspirin and clopidogrel in acute coronary syndromes: therapeutic insights from the CURE study Arch Intern Med 163 2003 1145 1153
15. S. Husted, H. Emanuelsson, S. Heptinstall, and et al. Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin Eur Heart J 27 2006 1038 1047
16. R.F. Storey, S. Husted, R.A. Harrington, and et al. Inhibition of platelet aggregation by AZD6140, a reversible oral P2Y12 receptor antagonist, compared with clopidogrel in patients with acute coronary syndromes J Am Coll Cardiol 50 2007 1852 1856
17. R.F. Storey, D.J. Angiolillo, S.B. Patil, and et al. Inhibitory effects of ticagrelor compared with clopidogrel on platelet function in patients with acute coronary syndromes: the PLATO (PLATelet inhibition and patient Outcomes) PLATELET substudy J Am Coll Cardiol 56 2010 1456 1462
18. K.P. Bliden, U.S. Tantry, R.F. Storey, and et al. The effect of ticagrelor versus clopidogrel on high on-treatment platelet reactivity: combined analysis of the ONSET/OFFSET and RESPOND studies Am Heart J 162 2011 160 165
19. M. Valgimigli Pretreatment with P2Y12 inhibitors in non-ST-segment-elevation acute coronary syndrome is clinically justified Circulation 130 2014 1891 1903
20. J.P. Collet, J. Silvain, A. Bellemain-Appaix, and et al. Pretreatment with P2Y12 inhibitors in non-ST-segment-elevation acute coronary syndrome: an outdated and harmful strategy Circulation 130 2014 1904 1914
21. F. Franchi, and D.J. Angiolillo Novel antiplatelet agents in acute coronary syndrome Nat Rev Cardiol 12 2015 30 47
22. L. Wallentin, D. Lindholm, A. Siegbahn, and et al. Biomarkers in relation to the effects of ticagrelor in comparison with clopidogrel in non-ST-elevation acute coronary syndrome patients managed with or without in-hospital revascularization: a substudy from the Prospective Randomized Platelet Inhibition and Patient Outcomes (PLATO) trial Circulation 129 2014 293 303
23. D.L. Bhatt, G.W. Stone, K.W. Mahaffey, and et al. Effect of platelet inhibition with cangrelor during PCI on ischemic events N Engl J Med 368 2013 1303 1313
24. S.D. Wiviott, E. Braunwald, C.H. McCabe, and et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes N Engl J Med 357 2007 2001 2015
25. G. Montalescot, L. Bolognese, D. Dudek, and et al. Pretreatment with prasugrel in non-ST-segment elevation acute coronary syndromes N Engl J Med 369 2013 999 1010
26. G.W. Stone, B. Witzenbichler, G. Weisz, and et al. Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): a prospective multicentre registry study Lancet 382 2013 614 623
27. G. Montalescot, A.W. van 't Hof, F. Lapostolle, and et al. Prehospital ticagrelor in ST-segment elevation myocardial infarction N Engl J Med 371 2014 1016 1027
28. J. Silvain, R.F. Storey, G. Cayla, and et al. P2Y12 receptor inhibition according to prehospital administration of ticagrelor in primary PCI for ST elevation myocardial infarction: the PRIVATE-ATLANTIC Study(abstr) J Am Coll Cardiol 65 2015 A53
29. G. Parodi, R. Valenti, B. Bellandi, and et al. Comparison of prasugrel and ticagrelor loading doses in ST-segment elevation myocardial infarction patients: RAPID (Rapid Activity of Platelet Inhibitor Drugs) primary PCI study J Am Coll Cardiol 61 2013 1601 1606
30. F. Franchi, F. Rollini, J.R. Cho, and et al. Impact of escalating loading dose regimens of ticagrelor in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: results of a prospective randomized pharmacokinetic and pharmacodynamic investigation J Am Coll Cardiol Intv 8 2015 1457 1467
31. G. Parodi, I. Xanthopoulou, B. Bellandi, and et al. Ticagrelor crushed tablets administration in STEMI patients: the MOJITO study J Am Coll Cardiol 65 2015 511 512
32. D.J. Angiolillo, D.J. Schneider, D.L. Bhatt, and et al. Pharmacodynamic effects of cangrelor and clopidogrel: the platelet function substudy from the cangrelor versus standard therapy to achieve optimal management of platelet inhibition (CHAMPION) trials J Thromb Thrombolysis 34 2012 44 55
33. 12-receptor inhibitors in patients with coronary artery disease Nat Rev Cardiol 13 2016 11 27